Are low concentrations of serum cholesterol associated with an increased risk of death from non-cardiovascular causes A meta-analysis of 18 separate cohort studies of 150 0002 men presented by D R Jacobs showed an increasing gradient of risk of death associated with increasing cholesterol for coronary heart disease as well as for all cardiovascular disease. In 11 studies of 120 000 women there was a similar gradient for coronary heart disease but not for all cardiovascular disease pooled. In women deaths from coronary heart disease (CHD) accounted for only about half of total cardiovascular mortality. In men a similar effect would be masked by the large number of coronary deaths. The implication of this might be that in women the likelihood of death from non-cardiac vascular diseases, such as stroke, was inversely related to serum cholesterol.
In both men and women the mortality from all non-cardiovascular causes was higher in those with serum cholesterol concentrations < 4 mmol/l. There were similar findings in the Multiple Risk Factor Intervention Trial (MRFIT) of 350 000 men. Lipid concentrations as low as < 4 mmol/l would never be an aim of therapy, so the argument about whether lowering cholesterol causes noncardiovascular disease is perhaps irrelevant. The suggested causal relation between noncardiovascular disease and low cholesterol is challenged by long-term studies that show that low serum cholesterol is associated with chronic ill health for many years before death.
A study of men aged 22 who were followed for 42 years showed that not only cardiovascular mortality but also non-cardiovascular mortality increased directly with serum cholesterol concentration.' G Davey Smith pointed out that the MRFIT trial,4 cited by Jacobs, showed that men aged 35-39 followed for 12 years demonstrated no relation between cholesterol and non-coronary mortality. The inverse relation was only apparent in elderly men, some of whom would be chronically sick. If the relation were causal, it would be expected in all cohorts. In the Renfrew and Paisley Study cholesterol was inversely related to lung cancer mortality.5 However, a cohort of similar size recruited in Glasgow at the same time from people who were all employed and might thus be expected to be more healthy showed no such relation. Furthermore in the Whitehall study when the confounding factors associated with increased mortality and low cholesterol were taken into account the associations between low cholesterol and increased non-coronary mortality were reduced or abolished.6 That cholesterol lowering in clinical trials (as opposed to spontaneously low concentrations) does not increase the risk of death from non-coronary disease was evident from a recently published meta-analysis of 35 cholesterol-lowering intervention trials in 57 000 patients.7 In this the degree to which cholesterol was reduced far from being associated with increasing non-cardiovascular mortality if anything, correlated with its decrease. In the meta-analysis presented by Davey Smith,7 of all identified randomised controlled trials of cholesterol-lowering treat-ments with a follow up of 6 months or more and with at least one death CHD mortality in individual trials differed more than 100-fold. Primary prevention trials clustered at the low end of the range of risk and secondary prevention trials at the upper end. The odds of dying of any cause in the treatment groups as compared with the control groups was significantly related (p < 0-001) to the risk of coronary heart disease in the control group. When the annual coronary heart disease mortality exceeded 3% all-cause mortality decreased in the intervention group, while at lower rates it increased.
An overall benefit of cholesterol lowering in high risk patients was strongly supported by other contributions. Lewis looked specifically at trials in patients with existing ischaemic heart disease7 12 in whom it is known that 50% of coronary deaths occur. 80% of all deaths in these trials were caused by coronary heart disease. Lewis also reviewed the findings of coronary angiographic studies that show that regression of coronary disease is possible with lipid-lowering therapy.'3-'7 One of the most striking findings was a 68% decrease in the need for coronary bypass surgery in patients whose cholesterol was reduced by 23% by partial ileal bypass surgery.16
Holme's meta-analysis, of more than 135 000 participants was larger than any other because it included trials in which the intervention was multifactorial and not confined to cholesterol lowering. 18 He too concluded that the likelihood of benefit from cholesterol-lowering was greatest in patients at high risk of coronary heart disease. His study indicated that in addition to patients with established coronary disease, symptomfree individuals with the highest cholesterol concentrations also stood to benefit.
The benefits of lowering cholesterol are therefore clearest in those with declared ischaemic heart disease and those with high cholesterol concentrations. There is no evidence of any beneficial effects on The total number of people participating in the trials was too small to yield sufficiently large numbers of deaths to draw any reliable conclusion.
The reason for the lack of favourable effect on all cause mortality in low risk individuals remains unexplained.
Are there particular high risk groups? G R Thompson described some of the high risk syndromes in which current evidence favours the introduction of lipid-lowering drugs even in the absence of CHD if dietary therapy alone proves ineffective. Patients with genetic hyperlipidaemia, particularly those with familial hypercholesterolaemia and type III hyperlipoproteinaemia, and people in whom polygenic dyslipidaemia was combined with multiple risk factors, such as a family history of ischaemic heart disease, diabetes mellitus, hypertension, and a long history of heavy cigarette smoking were often at sufficiently high risk to justify drug treatment.'920 Thompson Shortcomings of current evidence Meta-analysis, whatever its appeal to statisticians, cannot be more than a rough guide to the clinical value of intervention. Many of the trials included in meta-analysis were shortterm, lasting less than 2 years. In the metaanalysis presented by Peto and Collins the decrease in the incidence of coronary heart disease in trials lasting less than 2 years was 9% whereas in trials lasting longer it was 22%. Many of the trials included in the metaanalyses were analysed on an intention-totreat basis. That means that patients who did not comply with medication were included in the intervention group. In the Lipid Research Clinic Trial it was evident that the decrease in cholesterol in the intervention group as a whole was 8% and the decrease in coronary incidence 10%.23 It was estimated that in the patients who complied fully with medication the decrease in cholesterol was 25% and the decrease in coronary incidence 49%. 
